Targeted Therapies

Targeting CD133 in an in vivo ovarian cancer model reduces ovarian cancer progression.
Skubitz AP, Taras EP, Boylan KL, Waldron NN, Oh S, Panoskaltsis-Mortari A, Vallera DA.
Gynecologic Oncology. 2013 Sep;130(3):579-87. doi: 10.1016/j.ygyno.2013.05.027. PMID: 23721800.

View the full paper here

IL-15 super-agonist (ALT-803) enhances natural killer (NK) cell functino against ovarian cancer.

Felices M, Chu S, Kodal B, Bendzick L, Ryan C, Lenvik AJ, Boylan KLM, Wong HC, Skubitz APN, Miller JS, Geller MA.

Gynecologic Oncology. 2017;145(3):453-461. doi:10.1016/j.ygyno.2017.02.028. PMID: 28236454

View the full paper here. 

Cytokine-induced memory-like natural killer cells have enhanced function, proliferation, and in vivo expansion against ovarian cancer cells.

Uppendahl LD, Felices MD, Bendzick L, Ryan C, Kodal B, Hinderlie P, Boylan KLM, Skubitz APN, Miller JS, Geller MA.

Gynecologic Oncology. 2019 Apr;153(1):149-157. doi: 10.1016/j.ygyno.2019.01.006. PMID: 30658847

View the paper here.

Cytomegalovirus and systemic inflammation at time of surgery is associated with worse outcomes in serous ovarian cancer.
Wesley E, Uppendahl LD, Felices M, Dahl C, Messelt A, Boylan KL, Skubitz A, Vogel RI, Nelson HH, Geller MA.
Gynecologic Oncology. ePub 2020. doi:10.1016/j.ygyno.2020.10.029.

View the full paper here.